Citizens JMP lowered the firm’s price target on Prothena (PRTA) to $78 from $80 and keeps an Outperform rating on the shares. Prothena reported Q1 financial results and provided a business update, reiterating timelines for key clinical readouts in 2025. The firm says the stock is “compelling” ahead of the Phase 3 results for birtamimab in AL amyloidosis and PRX012 in Alzheimer’s disease.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTA:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue